Tech Company Inital Public Offerings
Stemline Therapeutics IPO
Stemline Therapeutics, based in New York, went public on 1/29/2013.
Transaction Overview
Company Name
Announced On
1/29/2013
Transaction Type
IPO
Amount
$33,000,000
Proceeds Purpose
Proceeds purposes are on file with company statements at the SEC.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
750 Lexington Ave. 11th Floor
New York, NY 10022
USA
New York, NY 10022
USA
Phone
Website
Email Address
Overview
Stemline Therapeutics, Inc. (NASDAQ: STML) is a clinical stage biotechnology company developing oncology compounds directed to cancer stem cell targets. Stemline's lead compound, SL-401, targets the interleukin-3 receptor present on multiple hematological cancers including leukemia and leukemia cancer stem cells.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ivan Bergstein
Chief Operating Officer
Kenneth Hoberman
VP - Finance
David Gionco
Browse more venture capital transactions:
Prev: 1/29/2013: Practically Green venture capital transaction
Next: 1/29/2013: WatchDox venture capital transaction
Share this article
Where The Data Comes From
We do our best to record tech company VC transactions. VC investment data records on this site are derived from publicly available VC deal announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs